Status:
COMPLETED
Hyperbaric Oxygen Therapy as a Neuroprotective Intervention in Pediatric Acquired Brain Injury With Cognitive Disability
Lead Sponsor:
Kafrelsheikh University
Conditions:
Hyperbaric Oxygen Therapy
Neuroprotective
Eligibility:
All Genders
4-12 years
Phase:
NA
Brief Summary
This research aimed to investigate the effectiveness of hyperbaric oxygen therapy as a neuroprotective strategy for improving neurological outcomes in pediatric patients who have sustained acquired br...
Detailed Description
Hyperbaric oxygen therapy (HBOT) is a medical treatment that delivers high-concentration oxygen in a pressurized chamber. It was developed initially from diving physiology research and popularized by ...
Eligibility Criteria
Inclusion
- Pediatric patients aged 4-12 years with acquired brain injury.
- Confirmed neurological sequelae (e.g., cardiac arrest, intracranial hemorrhage, central nervous system infections, stroke, tumor, hypoxia) via MRI/neurological exam.
Exclusion
- Positive family history of degenerative brain insults.
- Behavioral problems.
- Hyperbaric oxygen therapy contraindications:
- Active epilepsy.
- Respiratory insufficiency.
- Uncontrolled heart failure.
- Eustachian tube dysfunction.
- Tympanic membrane rupture.
- Mechanical ventilation dependency.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06954376
Start Date
March 1 2024
End Date
October 1 2024
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516